FDA
-
-
-
-
-
-
-
Karyopharm reports Q1 revenue up 17% as endometrial cancer study completes
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) PT Lowered to $5 at Leerink Partners
-
-
-
-
-
-
-
Registration Momentum Builds Across the Oncology Pipeline
-
-
-
-
-
-
-
Karyopharm secures $100 million financing, extends cash runway to Q2 2026
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
-
-
-
-
-
-
-
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

